TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trials for wet AMD. The company's other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors, Phase I/II clinical trials for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer. Its preclinical development product includes TRC694, an orally bioavailable inhibitor of NF-kB inducing kinase for the treatment of patients with hematologic malignancies, including myeloma. The company has a license agreement with Ambrx, Inc. for the development and commercialization of TRC105; and Santen Pharmaceutical Co., Ltd to develop, manufacture, and commercialize DE-122 for the ophthalmology indications of TRC105, as well as strategic licensing collaboration with Janssen Pharmaceutica N.V. to develop TRC253 and TRC694. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TCON
CUSIPN/A
Phone858-550-0780
Debt
Debt-to-Equity Ratio0.15
Current Ratio4.24
Quick Ratio4.24
Price-To-Earnings
Trailing P/E Ratio-2.59
Forward P/E Ratio-2.34
P/E GrowthN/A
Sales & Book Value
Annual Sales$8.76 million
Price / Sales5.88
Cash FlowN/A
Price / CashN/A
Book Value$0.96 per share
Price / Book3.02
Profitability
EPS (Most Recent Fiscal Year)($1.14)
Net Income$-19,100,000.00
Net Margins-201.21%
Return on Equity-82.47%
Return on Assets-47.74%
Miscellaneous
Employees25
Outstanding Shares17,750,000
TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions
What is TRACON Pharmaceuticals' stock symbol?
TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."
How were TRACON Pharmaceuticals' earnings last quarter?
TRACON Pharmaceuticals Inc (NASDAQ:TCON) announced its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.10. The biopharmaceutical company had revenue of $3 million for the quarter, compared to analysts' expectations of $3 million. TRACON Pharmaceuticals had a negative net margin of 201.21% and a negative return on equity of 82.47%. View TRACON Pharmaceuticals' Earnings History.
When is TRACON Pharmaceuticals' next earnings date?
What price target have analysts set for TCON?
1 equities research analysts have issued 1 year price targets for TRACON Pharmaceuticals' stock. Their predictions range from $8.00 to $8.00. On average, they anticipate TRACON Pharmaceuticals' stock price to reach $8.00 in the next twelve months. View Analyst Ratings for TRACON Pharmaceuticals.
Who are some of TRACON Pharmaceuticals' key competitors?
Some companies that are related to TRACON Pharmaceuticals include Fennec Pharmaceuticals (FENC), Compugen (CGEN), Organovo (ONVO), Eiger Biopharmaceuticals (EIGR), Krystal Biotech (KRYS), Aptose Biosciences (APTO), Pluristem Therapeutics (PSTI), Cidara Therapeutics (CDTX), Brainstorm Cell Therapeutics (BCLI), Genocea Biosciences (GNCA), Applied Genetic Technologies (AGTC), Curis (CRIS), Aevi Genomic Medicine (GNMX), Champions Oncology (CSBR) and BioCardia (BCDA).
Who are TRACON Pharmaceuticals' key executives?
TRACON Pharmaceuticals' management team includes the folowing people:
- Dr. Charles P. Theuer, CEO, Pres & Director (Age 54)
- Ms. Patricia L. Bitar, Chief Financial Officer, Treasurer and Assistant Sec. (Age 59)
- Mr. H. Casey Logan, Chief Bus. Officer (Age 46)
- Dr. Sharon Real Ph.D., Sr. VP of Product Devel. (Age 54)
- Ms. Bonne Adams M.B.A., Sr. VP of Clinical Operations (Age 41)
When did TRACON Pharmaceuticals IPO?
(TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.
Has TRACON Pharmaceuticals been receiving favorable news coverage?
News headlines about TCON stock have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. TRACON Pharmaceuticals earned a coverage optimism score of 0.09 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 47.02 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are TRACON Pharmaceuticals' major shareholders?
TRACON Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include PUISSANCE CROSS-BORDER OPPORTUNITIES V LLC (15.50%), NEA Management Company LLC (19.53%), Alambic Investment Management L.P. (0.52%) and X Square Capital LLC (0.45%). Company insiders that own TRACON Pharmaceuticals stock include Enterprise Associates 14 New, Peter W Sonsini and William R Larue. View Institutional Ownership Trends for TRACON Pharmaceuticals.
Which institutional investors are selling TRACON Pharmaceuticals stock?
Which institutional investors are buying TRACON Pharmaceuticals stock?
TCON stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC and Alambic Investment Management L.P.. Company insiders that have bought TRACON Pharmaceuticals stock in the last two years include Enterprise Associates 14 New and Peter W Sonsini. View Insider Buying and Selling for TRACON Pharmaceuticals.
How do I buy shares of TRACON Pharmaceuticals?
Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TRACON Pharmaceuticals' stock price today?
One share of TCON stock can currently be purchased for approximately $2.90.
How big of a company is TRACON Pharmaceuticals?
TRACON Pharmaceuticals has a market capitalization of $52.36 million and generates $8.76 million in revenue each year. The biopharmaceutical company earns $-19,100,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. TRACON Pharmaceuticals employs 25 workers across the globe.
How can I contact TRACON Pharmaceuticals?
TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]
MarketBeat Community Rating for TRACON Pharmaceuticals (TCON)
MarketBeat's community ratings are surveys of what our community members think about TRACON Pharmaceuticals and other stocks. Vote "Outperform" if you believe TCON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCON will underperform the S&P 500 over the long term. You may vote once every thirty days.
